Videos

Watch Dr. Aaron S. Mansfield, from Mayo Clinic, discuss the management of mesothelioma during the CURE Educated Patient Lung Cancer Summit.

Watch Dr. David Gerber, from UT Southwestern Medical Center, discuss antibody drug conjugates during the CURE Educated Patient Lung Cancer Summit.

Watch Dr. Hossein Borghaei, Dr. Jared Weiss and Dr. Anne Chiang answer questions about early disease management during the CURE Educated Patient Lung Cancer Summit.

Patients with lung cancer must be educated about their disease in their native language to become better advocates for themselves, an expert explained.

Watch Dr. Anne Chiang, from Yale School of Medicine, discuss molecular testing and adjuvant targeted therapies during the CURE Educated Patient Lung Cancer Summit.

Watch Dr. Jared Weiss, from UNC School of Medicine, discuss neoadjuvant versus adjuvant therapy during the CURE Educated Patient Lung Cancer Summit.

As part of its Speaking Out video series, on behalf of Fans for the Cure, CURE® spoke with Dr. Daniel P. Petrylak about survivorship in prostate cancer.

As part of its Speaking Out video series, on behalf of Fans for the Cure, CURE® spoke with Dr. Daniel P. Petrylak about the long-term effects associated with a prostate cancer diagnosis.

As part of its Speaking Out video series, on behalf of Fans for the Cure, CURE® spoke with Dr. Daniel P. Petrylak about PSMA, what it is and how it is advancing the prostate cancer landscape.

As part of its Speaking Out video series, on behalf of Fans for the Cure, CURE® spoke with Tony Crispino about the importance of patient-physician communication in prostate cancer.

As part of its Speaking Out video series, on behalf of Fans for the Cure, CURE® spoke with Tony Crispino about seeking support after a prostate cancer diagnosis.

A breast cancer research nurse and lung cancer survivor stresses the importance of participating in clinical trials that are investigating the latest treatments.

Lung cancer advocates and clinicians must ”fight” for every patient with the disease and ensure that the most amount of people can benefit from advancements in the field, according to an advocate.

As part of its “Speaking Out” video series, CURE spoke with Dr. Tracy L. Rose, on behalf of the Bladder Cancer Advocacy Network, about support available for patients and caregivers following a bladder cancer diagnosis.

As part of its “Speaking Out” video series, CURE spoke with Dr. Tracy L. Rose, on behalf of the Bladder Cancer Advocacy Network, about the role of the caregiver in bladder cancer and how they can also seek support to aid them.

As part of its “Speaking Out” video series, CURE spoke with Dr. Tracy L. Rose, on behalf of the Bladder Cancer Advocacy Network, about how patients can find clinical trials they may be eligible for.

As part of its “Speaking Out” video series, CURE spoke with Dr. Tracy L. Rose, on behalf of the Bladder Cancer Advocacy Network, about letting physicians know about patient preferences to improve communication and select the right treatment option.

As part of its “Speaking Out” video series, CURE spoke with Dr. Tracy L. Rose, on behalf of the Bladder Cancer Advocacy Network, about how currently available agents are being investigated in combination with one another.

Melanoma of the skin has been shown to be greatly associated with exposure to sunlight, whereas uveal melanoma — commonly known as cancer of the eye — is not.

An expert explains how antibody drug conjugates work to treat cancer.

Sunandana Chandra, MD, MS, closes by sharing advice for patients with metastatic uveal melanoma.

An overview of the treatment options for patients with mUM who ineligible for treatment with tebentafusp.

In recent years, immunotherapy’s usage has expanded for the treatment of patients with kidney cancer.

Dr Sunandana Chandra highlights her personal experience in prescribing tebentafusp and other therapies for mUM, and discusses the educational resources and advocacy organizations that she encourages patients to look into to help make an informed decision about their treatment regimens.

An oncologist outlines which patients with mUM are eligible for bispecific T-cell receptor immunotherapy, discusses logistical and safety considerations, and explains why pre-treatment HLA testing is required for those considering the regimen.

Sunandana Chandra, MD, MS, discusses safety and efficacy data from the IMCgp100-202 trial on tebentafusp, and comments on the clinical implications of these data.

An expert provides an overview of the historical and currently available treatment options in metastatic uveal melanoma (mUM), including the bispecific T-cell receptor immunotherapy tebentafusp (“teh-BEN-tah-fuhsp”).

A psychiatrist advises patients with cancer to speak up about their mental health concerns during cancer treatment, as there are tools that can guide best next steps.